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Synthetic long non-coding RNAs 
[SINEUPs] rescue defective gene 
expression in vivo
Alessia Indrieri1, Claudia Grimaldi1, Silvia Zucchelli2,3, Roberta Tammaro1,  
Stefano Gustincich2,4,5 & Brunella Franco1,6
Non-coding RNAs provide additional regulatory layers to gene expression as well as the potential 
to being exploited as therapeutic tools. Non-coding RNA-based therapeutic approaches have been 
attempted in dominant diseases, however their use for treatment of genetic diseases caused by 
insufficient gene dosage is currently more challenging. SINEUPs are long antisense non-coding RNAs 
that up-regulate translation in mammalian cells in a gene-specific manner, although, so far evidence of 
SINEUP efficacy has only been demonstrated in in vitro systems. We now show that synthetic SINEUPs 
effectively and specifically increase protein levels of a gene of interest in vivo. We demonstrated that 
SINEUPs rescue haploinsufficient gene dosage in a medakafish model of a human disorder leading to 
amelioration of the disease phenotype. Our results demonstrate that SINEUPs act through mechanisms 
conserved among vertebrates and that SINEUP technology can be successfully applied in vivo as a new 
research and therapeutic tool for gene-specific up-regulation of endogenous functional proteins.
Both naturally occurring and artificial RNAs have the potential to be used as modulators of target genes. 
Regulation of gene expression through the activity of gene-specific artificial inhibitory nucleic acids such as siR-
NAs, RNAi and morpholinos (MOs) has become a common strategy to investigate gene function and they have 
also extended the druggable genome to potentially all protein coding genes. An equally important approach with 
potentially broad-range applications could be based on natural and artificial RNAs that can increase expression 
of target genes and few examples have been described. For instance, degradation or inhibition in vivo of natural 
antisense transcripts (NATs) by single-stranded oligonucleotides or siRNAs can transiently and reversibly modu-
late locus-specific gene expression1 and chemically modified mRNAs are capable to modulate gene expression in a 
mouse model of a lethal congenital lung disease2. Finally, a programmable transcription factor prototype has been 
shown to promote gene transcription in cell lines and primary cultures via an invariable transactivating domain 
coupled with a variable RNA domain that binds genes using sequence specificity3.
Large genomic efforts such as ENCODE4 and FANTOM5 have shown that the majority of the mammalian 
genome is transcribed. In addition to approximately 25000 protein-coding genes, there are at least an equal num-
ber of long non-coding RNA (lncRNA) genes that generate long transcripts (over 200 base pairs) that do not 
encode for proteins. About one third of annotated lncRNAs overlaps with protein-coding genes and many of 
these are transcribed from the opposite strand forming sense/antisense (S/AS) pairs6.
We have previously shown that a natural lncRNA antisense to the Ubiquitin carboxyl-terminal ester-
ase L1 (AS Uchl1), a Parkinson’s disease-associated gene, is able to increase UchL1 protein synthesis at the 
post-transcriptional level7. We demonstrated that AS Uchl1 activity depends on two distinct RNA elements, 
The Binding Domain (BD) at the 5′ end, is a sequence that overlaps, in antisense orientation, to the sense 
protein-coding mRNA and determines target selection and AS Uchl1 specificity by RNA-RNA base pairing. The 
AS Uchl1 BD is 72bp long, centered across the initiating ATG with a −40/+32 configuration, spans part of the 
Uchl1 5′UTR and a portion of its coding sequence (CDS)7. The other functional part of the AS Uchl1 sequence is 
represented by the Effector Domain (ED), an inverted SINE (short interspersed nuclear elements) B2 sequence 
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embedded in the non-overlapping part of the transcript that is essential for protein synthesis up-regulation7. 
Its modular architecture allows to redirect translation enhancement activity to any target mRNA by swapping 
its BD with the appropriate antisense sequence8. The AS Uchl1 domain organization is conserved in other AS 
lncRNAs that overlap with protein coding genes and regulate their translation7,9. Therefore, AS Uchl1 repre-
sents a new class of natural and synthetic antisense lncRNAs that can activate translation7,10. These RNAs were 
named SINEUPs because they require the inverted SINEB2 sequence to UP-regulate translation in a gene-specific 
manner10. Synthetic SINEUPs have been proven effective in vitro with a number of targets, including GFP7,10, 
FLAG-tagged proteins10 and secreted recombinant antibodies9, thus supporting the intrinsic scalability of 
SINEUP technology10.
However, to date SINEUP efficacy has only been limited to measuring target protein levels in vitro in mamma-
lian cells, in experiments carried out in controlled, homogenous cell culture systems.
Here we show for the first time that SINEUPs can increase the synthesis of a functional endogenous protein 
in vivo and rescue haploinsufficient gene dosage in a medakafish model of a human disease.
Our study demonstrates that SINEUPs may be an effective tool for functional studies in vivo that demand 
increased levels of endogenous proteins. In addition, these results are a proof of principle that this technology 
may be applicable to design therapeutic approaches for genetic diseases in which selectively increasing the expres-
sion of the target gene may be curative.
Results and Discussion
To assess the potential application of the SINEUP technology in vivo, we used the teleost medakafish (Oryzias 
latipes), which is particularly amenable for reverse-genetic analyses. In this model, the microinjection of early 
embryos with any kind of RNAs is technically easy and results in transient gene overexpression or inhibition11.
For our initial studies we utilized the SINEUP-GFP7 that results in an increase GFP protein levels in transient 
overexpression experiments. SINEUP-GFP was cloned into the pCS2 plasmid that allows in vitro synthesis of 
RNA. As expected, we observed that in human embryonic kidney (HEK) 293T/17 cells, the SINEUP-GFP pCS2 
construct increased GFP protein levels by acting post-transcriptionally (Fig. 1). To test their functionality in vivo, 
SINEUP-GFP RNA and GFP mRNA were transcribed in vitro and then co-injected into medaka embryos. Equal 
amounts of RFP transcribed mRNA were also co-injected as control for SINEUP specificity. SINEUP activity 
was estimated as fold change in GFP protein levels, normalized for RFP protein levels, in the presence or absence 
of the SINEUP. Embryos injected with the SINEUP-GFP displayed increased GFP levels and unchanged RFP 
levels (Fig. 2a,b). Furthermore, western blot (WB) analysis confirmed increased GFP levels at 19 and 30 stage 
(st) embryos (Fig. 2c,d). These results demonstrate the efficacy of SINEUPs and validate the post-transcriptional 
mechanisms of SINEUPs in vivo. SINEB2 sequences are mouse specific and are not present in fish, in which a 
superfamily of vertebrate SINEs (V-SINEs) has been described12. Our results indicate that SINEUPs act through 
mechanisms conserved among vertebrates and suggest that the secondary structure of SINEs is functionally con-
served between mice and fish.
To address the potential use of this technology in increasing expression of an endogenous protein in vivo we 
tested SINEUPs in a medakafish model of microphthalmia with linear skin defects (MLS) syndrome, a X-linked 
dominant disorder characterized by microphthalmia, brain abnormalities and skin defects in heterozygous 
females, and in utero lethality in males13. MLS syndrome is caused by mutations in players of the mitochon-
drial respiratory chain (MRC) such as the holocytochrome c-type synthase (HCCS)14, and the subunit 7B of 
cytochrome c oxidase (COX), the MRC complex-IV15.
We downregulated cox7B expression using a MO-based approach. cox7B-MO was designed against the exon 
2 acceptor splice-site and its injection causes exon 2 skipping resulting in frameshift15 (Fig. 3a). We designed a 
synthetic SINEUP against the endogenous cox7B mRNA carrying a 72bp BD starting from position −40 in the 
5′UTR (before ATG) to position +32 in the CDS (Fig. 3a). We then cloned the SINEUP-cox7B sequence in the 
pCS2 plasmid and injected the in vitro synthesized RNA into embryos. As expected, injection of SINEUP-cox7B 
did not change cox7B mRNA levels (Supplementary Fig. 1a) and did not induce any aberrant phenotype in con-
trol embryos (Fig. 3b,c). cox7B-morphants showed a dose-dependent phenotype characterized by microcephaly 
and microphthalmia15  (Fig. 3b,c). Interestingly, injection of the SINEUP-cox7B in MLS morphants fully rescued 
microphthalmia and microcephaly in about 50% of embryos, whereas the injection of a control SINEUP car-
rying a scrambled sequence in the BD domain (SINEUP-SCR) did not result in amelioration of the phenotype 
(Fig. 3b,c).
To exclude that SINEUP could induce changes in cox7B transcription and/or interfere with MO function-
ing in cox7B morphants, we performed RT-PCR to amplify full-length WT and mutant cox7B mRNAs from 
cox7B-MO injected embryos and embryos co-injected with cox7B-MO and SINEUP-cox7B. Target sequences of 
cox7B-MO and SINEUP-cox7B are localized in different exons of cox7B and do not overlap (Fig. 3a). As expected, 
SINEUP-cox7B did not alter size or abundance of WT and mutated cox-7B mRNA (Fig. 3d,e) thus confirming 
that SINEUPs act through a post-transcriptional mechanism.
COX7B is necessary for complex-IV formation and its downregulation in vitro induces reduction of fully 
assembled complex-IV and of its subunits including COX-IV15 (Supplementary Fig. 2). As expected WB analysis 
showed reduction of cox-IV in cox7B-MO-injected fish (Fig. 3f,g). Interestingly, SINEUP-cox7B was capable to 
fully rescue cox-IV levels in cox7B-morphants whereas no effect was detected using the SINEUP-SCR in cox7B 
morphants (Fig. 3f,g and Supplementary Fig. 3) or the SINEUP-cox7B in wt embryos (Supplementary Fig. 1b,c).
We previously demonstrated that, in hccs-morphants, MRC impairment results in increased CNS pro-
grammed cell death (PCD) and that this event underlies the MLS phenotype16. Interestingly, TUNEL analy-
sis revealed an increase of PCD in the eyes and brain of cox7B morphants, which was rescued by injection of 
SINEUP-cox7B (Fig. 4a,b).
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Our data demonstrated that synthetic SINEUP-cox7B may restore MRC function thus consequently rescuing 
the MLS phenotype. Our results validate SINEUPs as a versatile tool for in vivo experimental biology and pave 
the way for its use in RNA therapeutics.
Artificial siRNAs, RNAi and MOs have become the tools of choice to inhibit gene expression and SINEUPs 
represent their molecular counterparts to increase protein synthesis in vivo. To our knowledge, SINEUPs rep-
resent the only available tool that uses AS lncRNAs to enhance production of endogenous proteins acting on 
their cellular mRNAs. In this context, SINEUP technology represents a powerful tool in molecular biology to 
Figure 1. pCS2 + -SINEUP-GFP activity in vitro. HEK293T/17 were transfected with pEGFP-C2 and 
pCS2+/SINEUP-GFP constructs at 1:6 ratio (+SINEUP). Control cells were transfected with pEGFP-C2 and 
an empty control plasmid (-SINEUP). 48 hr after transfection, cells were lysed and processed for protein (a) and 
RNA (b) levels. Western blot was performed with anti-GFP antibody. β-actin was used as loading control. Fold-
induction was calculated on Western blot images normalized to β-actin and relative to empty control samples. 
Expression of SINEUP-GFP (white bars) and quantity of GFP mRNA (grey bars) were monitored by Real Time 
PCR using specific primers. Data indicate mean ± SD. Data are representative of >3 independent replicas.
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increase protein levels of the specific gene of interest in vivo. Given their mode of action, SINEUPs would allow a 
spatio-temporal regulation of protein quantities in a more physiological context, avoiding artifacts due to ectopic 
overexpression and targeting only cells that actively express mRNA of interest, while being ineffective if mRNA 
is not present or present in a mutated form. On the basis of our results, SINEUPs should be considered a new 
approach to treat conditions such as haploinsufficiencies due to a reduction to 50% or less of gene function in 
which rescue of the phenotype requires recovery of the protein levels. A large number of genetic disorders are due 
to reduced levels of protein products. For these conditions, an efficient SINEUP activity specific for the gene of 
interest would, in principle, be therapeutic. This approach presents several advantages over competing technolo-
gies: a) SINEUPs can modulate translation of target mRNAs without introducing stable genomic changes; b) the 
induced up-regulation of specific proteins is a physiological range (~2-fold) compared to most conventional gene 
replacement strategies; c) SINEUPs exert their function on target mRNAs under their physiological regulation 
thus limiting adverse influences on cells and tissues that do not express the target transcript8,17.
In conclusion our data demonstrate that SINEUPs can selectively increase the expression of an endogenous 
functional protein in vivo and may be applied as a new tool in molecular biology and for nucleic acids-based 
therapeutics.
Methods
Plasmids. pEGFP-C2 (Clontech), SINEUP targeting EGFP (here named SINEUP-GFP), and SINEUP con-
taining a scramble sequence in the region of overlap (Binding Domain, BD) (here named SINEUP-SCR) have 
been previously described7.
SINEUP targeting medakafish cox7B mRNA (Accession Number HE717026) was constructed using pcD-
NA3-Δ5-ASUchl1 as backbone7. SINEUP-backbone lacks the BD to Uchl1 and retains AS Uchl1 effector domain 
(inverted SINEB2 element) embedded in AS Uchl1 non-overlapping sequence containing the partial Alu 
sequence and the 3′ tail. SINEUP cox7B-specific BD (72bp) was designed, in antisense orientation, around the 
ATG of the protein-coding sequence with a −40/+32 organization. For antisense cox7B, the method of ‘annealing 
Figure 2. Synthetic SINEUP increases GFP protein levels in vivo. (a) Representative st19 embryos injected 
with RFP and GFP mRNA with or without SINEUP-GFP RNA. Scale bar 100 μm. (b) Quantification of GFP/
RFP fluorescence intensity by ImageJ analysis software (n = 10, ***p < 0,001, one-tailed Student’s t-test; Error 
bars are SEM). (c) WB analysis of GFP in st19 and st30 embryos injected as in (a). (d) Quantification of GFP 
protein levels (n = 2, *p < 0,05, **p < 0,01, one-tailed Student’s t-test; Error bars are SEM).
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and primer extension’ of two 3′-end overlapping oligonucleotides was used to generate the 72-bp antisense cox7B 
overlap region. Annealed fragment was obtained with the following oligonucleotides:
Figure 3. Synthetic SINEUP-cox7B rescues MLS phenotype in medakafish. (a) Structure of the medakafish 
cox7B transcript (exon/intron gene organization is displayed) and binding sites of cox7B-MO and SINEUP-
cox7B. The cox7B-MO was designed against the acceptor splice site of exon 2 and its injection causes the 
skipping of exon 2. The BD of SINEUP-cox7B is designed against exon 1 in position −40 in the 5′-UTR (before 
ATG) to position +32 in the CDS. (b) Representative st30 embryos injected with control-MO, SINEUP-cox7B,  
cox7B-MO with or without SINEUP-cox7B or SINEUP-SCR. Scale bars 100 μm. SINEUPs rescue microphthalmia  
and microcephaly in 50% of cox7B-morphants (c). (n ≥ 300 embryos/conditions, ***p < 0,001, One-way 
ANOVA; Error bars are SEM). (d) RT-PCR of cox7B transcripts on total RNA extracted from embryos injected 
with control-MO, cox7B-MO and embryos co-injected with cox7B-MO and cox7B-SINEUP. Black arrow 
indicates WT mRNA whereas the red arrow indicates the mutated mRNA generated by cox7B-MO-driven 
aberrant splicing. (e) Real Time PCR on total RNA using specific primers to amplify WT cox7B mRNA. 
(n = 3 independent biological samples, ***p < 0,001, **p < 0,01, two-tailed Student’s t-test; Error bars are 
SEM). (f) WB analysis of cox-IV in st30 embryos injected with control-MO and cox7B-MO with or without 
SINEUP-cox7B. (g) Quantification of cox-IV protein levels (n = 3, **p < 0,01 one-tailed Student’s t-test; Error 
bars are SEM).
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AScox7BFW 5 ′-ATATCTCGAGATGT TAGCTGCAGCCT T TGCAAACCGGTACATGT TGTCT 
GGCCTTGTG-3′
AScox7BRv 5′-GAGAGATATCCCGTTCTTCAAGGGTATCTGAAGACACAAGGCCAGACAACATGTA 
CC-3′
The annealed fragment was digested with XhoI and EcoRV and ligated into antisense pcDNA3-Δ5-ASUchl1.
Full-length GFP from pEGFP-C2 plasmid and full-length SINEP-GFP, SINEUP-SCR and SINEUP-cox7B 
from pcDNA3 plasmids were cloned into with pCS2+ vector.
pCS2+/RFP (Red Fluorescent Protein) was already described16.
Cell lines and transfection. Human Embryonic Kidney (HEK) 293T/17 and HeLa cells were obtained from 
ATCC and maintained in culture with Dulbecco’s Modified Eagle Medium (GIBCO) supplemented with 10% FBS 
(SIGMA) and 1% antibiotics (penicillin/streptomycin), as suggested by the vendor.
HEK 293T/17 cells were transfected with Fugene HD (Roche), with a 1:6 ratio between pEGFP-C2 vector and 
pCS2+/SINEUP-GFP plasmids and following manufacture’s instruction. Cells were collected at 48 hours after 
transfection and split in two samples for RNA extraction and Western Blot analysis, as previously described10.
To silence COX7B, Hela cells were transfected using siRNAs ON-TARGET against human COX7B and 
ON-TARGET Non-Targeting (Darmachon) to a final concentration of 50 nM using Interferin reagent as previ-
ously described15. Cells were collected at 72 hr after transfection for protein extraction and Western Blot analysis.
Medakafish (Oryzias latipes) Stocks. Wild type Oryzias latipes of the cab strain were maintained in an 
in-house facility (28 °C on a 14/10 hr light/dark cycle). Embryos were staged as described18.
All studies on fish were conducted in strict accordance with the institutional guidelines for animal research 
and approved by the Italian Ministry of Health; Department of Public Health, Animal Health, Nutrition and Food 
Safety in accordance to the law on animal experimentation (article 7; D.L. 116/92; protocol number: 00001/11/
IGB; approval date June 6, 2011). Furthermore, all animal treatments were reviewed and approved in advance by 
the Ethics Committee of the Institute of Genetics and Biophysics, IGB Animal House, (Naples, Italy).
mRNAs and MOs Injections. RNAs of SINEP-GFP, SINEUP-SCR, SINEUP-cox7B, GFP and RFP were 
transcribed in vitro from pCS2+ plasmids using the SP6 mMessage mMachine kit (Ambion) according to the 
Figure 4. cox7B downregulation induces increased cell death that is rescued by synthetic SINEUP-cox7B. 
(a) TUNEL assays on retinal sections of st30 embryos injected with control-MO, cox7B-MO with or without 
SINEUP-cox7B or SINEUP-SCR. Scale bars 20 μm. (b) Number of TUNEL positive cells/eye (n ≥ 5 retina/
condition, **p < 0,01, ***p < 0,001, One-way ANOVA; Error bars are SEM).
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manufacturer’s instructions. Control-MO (5′-CCTACCTACACCACAACAGAAATAA-3′) and cox7B-MO 
(5′-CCGACCTGCACGACAACACAAAGAA-3′) were purchased from Gene Tools, LLC. MOs working con-
centrations, injection conditions and their specificity and efficiency were previously described15. MOs and 
RNAs were injected into fertilized embryos at the one/two-cell stage according to the following conditions: GFP 
mRNA 50 ng, RFP mRNA 50 ng, SINEUP-GFP 300 ng, control-MO and cox7B-MO 100 μM, SINEUP-cox7B and 
SINEUP-SCR 300 ng. At least 3 independent experiments were performed for each condition.
mRNA expression analysis. Total RNA extraction from cells and embryos was done using RNeasy Mini 
kit (Quiagen) according to the manufacturer’s instructions. During the extraction protocol RNAs were digested 
with DNaseI (Qiagen) to remove DNA contaminating, according to the manufacturer’s instructions. At least 50 
embryos were pooled in each assay. Total RNA was then reverse-transcribed into cDNA by QuantiTect Reverse 
Transcription Kit (Quiagen) with random hexamers oligo.
For RT-PCR experiment, full length cox7B transcripts were amplified from cDNAs of control-MO, 
cox7B-MO and cox7B-MO + SINEUP-cox7B using the following primers designed against the exon 1 and exon 
3 respectively:
cox7BEx1Fw 5′-CGCAACCATTTCCGGTATCTG-3′
cox7BEx3Rw 5′-GGTATTGGTTTGTCATCTGTAC-3′
PCR fragments were loaded on 2% agarose gel and subjected to electrophoresis.
For quantitative real time PCR analysis (qRT-PCR), cDNAs was diluited 1:2 and analyzed using Roche Light 
Cycler 480 system with LigthCycler 480 SYBR Green I Master (Roche). Oligonucleotide sequences of GFP and 
human GAPDH primers were previously described7. To specifically amplify WT medakafish cox7B mRNA, we 
used the following primers designed against the exon 3 and exon 2 that is skipped after the MO-driven aberrant 
splicing15:
cox7BEx2Fw 5′-CAGTGGAACCGTCTTCTGC-3′
cox7BEx3Rw 5′-GGTATTGGTTTGTCATCTGTAC-3′
Medakafish hprt and gapdh primers were previously described19,20 and used as endogenous controls. mRNA 
analysis showed comparable results with both normalization approaches. Relative expression was calculated with 
the ΔΔCt method21 and variation was reported as fold change (2−ΔΔCt). The results are shown as means ± SEM 
of three independent biological assays.
Protein extracts and Western blot analysis. Cells or embryos (at least 100 for conditions) were lysed 
in RIPA buffer containing 1X protease inhibitor cocktail (SIGMA). Cleared proteins extracts were quantified 
by using the Bradford method (Bio-Rad). For WB, protein samples were separated on 15% SDS-PAGE and 
transferred to PVDF membrane (Millipore). Membranes were blocked in TBS containing 5% Non Fat Dry 
Milk (Cell Signaling) and incubated with the follows primary antibodies: anti-GFP 1:500 (Abcam, ab13970), 
anti GFP rabbit polyclonal antibody (Life technologies, a6445), used 1:1000 (for HEK 293T/17 cells experi-
ments), anti-β-Actin 1:500 (Sigma), anti-GAPDH 1:1000 (Santa Cruz Biotechnology), anti-COX-IV 1:500 (Cell 
Signaling), anti-COX7B 1:500 (Abcam, ab137094).
Proteins of interest were detected with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG 
antibody (1:3000, GE Healthcare) and rabbit anti-chicken IgY antibody (Millipore) visualized with the Luminata 
Crescendo substrate (Millipore) or the Super Signal West Femto substrate (Thermo Scientific), according to the 
manufacturer’s protocol. Western blotting images were acquired using the Chemidoc-lt imaging system (UVP) 
and band intensity was calculated using ImageJ software.
TUNEL assay. TUNEL assays were performed on st30 embryos using In Situ Cell Death Detection Kit 
(Roche, Mannheim, Germany) as previously reported16.
Statistical Analysis. In all experiments the significance of differences between groups was evalu-
ated by ANOVA and Student’s t-test, p < 0.05 was considered significant. Quantitative data are presented as 
the mean ± SD (Standard Deviation) or ± SEM (Standard Error of the Mean) of at least three independent 
experiments.
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